Reach FDA_21_CFR_PART_312 readiness without rebuilding your policy programme
FDA 21 CFR Part 312 governs Investigational New Drug (IND) applications — required before a drug can be shipped across state lines for clinical investigation. Covers commercial vs treatment vs investigator-sponsored INDs, content + format (Form FDA 1571), safety reporting (IND Safety Reports per §312.32 / 7- or 15-day timelines), clinical hold authorities, sponsor obligations + investigator obligations. Failure to comply has resulted in clinical holds + sponsor + investigator disqualification. Quick Policy maps FDA_21_CFR_PART_312 into the policy families, controls, and evidence your team needs — and keeps it current between audits.
FDA_IND
Framework
US
Jurisdiction
Supervisory
Assurance
365 days
Review cadence
FDA_21_CFR_PART_312 quick answer
Standard facts
Framework: FDA_IND
Authority: US Food and Drug Administration (FDA / CDER + CBER)
Jurisdiction: US
Why FDA_21_CFR_PART_312 matters for your operating model
FDA_21_CFR_PART_312 doesn't just dictate document templates — it shapes which controls auditors test, what evidence they ask for, and which gaps surface first during diligence. Getting it wrong creates renewal slippage, audit findings, and stalled customer deals.
- • Issued by US Food and Drug Administration (FDA / CDER + CBER) and primarily enforced in US.
- • Directly shapes policy families including Clinical Trials, Pharmacovigilance — these are the artefacts assessors open first.
- • Common artifacts include Policy.
- • Obligation model: Mandatory In Scope — meaning you need defensible reasoning for in-scope vs out-of-scope decisions, not just signed policies.
How Quick Policy helps you stand up FDA_21_CFR_PART_312
The platform turns FDA_21_CFR_PART_312 from a PDF of requirements into a live operating model — policies, training, evidence, and audit-export packs that update in lock-step when the standard or your business changes.
- • Adopt FDA_21_CFR_PART_312 once and Quick Policy seeds the right policy families (Clinical Trials, Pharmacovigilance) with applicability rationale your auditor can follow.
- • Common artifacts include Policy.
- • Review cadence is enforced at ~365 days so policies don't silently expire ahead of recertification.
- • Standard updates (FDA_21_CFR_PART_312 revisions, errata, regulator guidance) trigger an applicability re-check across your active policies — not a full rewrite.
Policy families commonly involved
Recommended artifacts and context
Industry tags: LIFE_SCIENCES
Obligation model: Mandatory In Scope
Coverage depth: Profile
How Quick Policy operationalizes FDA_21_CFR_PART_312
Turn standards context into drafting, review, training, and evidence workflows that are easier to maintain over time.
Capture Core Profile
Admins complete adaptive onboarding to establish operating model, risk posture, and compliance objectives.
Determine Applicable Standards
Standards applicability ranks obligations by industry, geography, services, and data profile.
Generate and Harmonise Policy
Three-pass generation drafts, repairs contradictions, and validates coverage before reviewer handoff.
Review and Approve
Approvers validate policy language, mappings, and obligations using structured workflow stages.
Need adjacent guidance?
Use these pages for broader platform, industry, or buying context around FDA_21_CFR_PART_312.